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CD4+ T cell responses after vaccination or in­
fection show substantial heterogeneity in terms 
of their phenotype and functional capacity. In­
ducing protective responses without the appro­
priate  means  to  assess  such  heterogeneity  has 
limited the ability to define correlates of protec­
tion after vaccination. Thus, understanding the 
type of CD4+ T cell response required to medi­
ate protection is critical for rational design of 
vaccines  against  infections  requiring  Th1  im­
munity. Historically, T cell responses have been 
characterized by magnitude (frequency), prolif­
erative capacity, or the mean TCR avidity. Re­
cently, multicolor flow cytometry has broadened 
the spectrum of parameters that can be measured 
simultaneously at the single­cell level to include 
phenotypic markers and/or specific combina­
tions of functional responses (e.g., cytokines). 
This  more  extensive  characterization,  termed 
quality, is defined by the pattern of cytokine 
production at the single­cell level (Seder et al., 
2008). The quality can be related to the spectrum 
of  Th1  differentiation  from  IFN­–negative, 
IL­2–producing, and/or TNF­producing cen­
tral  memory  cells  to  multifunctional  IFN­+ 
IL­2+TNF+  or  IFN­+IL­2TNF+  effector 
memory cells to terminally differentiated IFN­ 
single­positive cells (Seder et al., 2008; Wu et al., 
2002). Furthermore, when quantified on a per­
cell basis, Th1 cells secreting all three cytokines 
(IFN­+IL­2+TNF+) produce considerably more 
IFN­ than double­ or single­producing IFN­ 
cells (Darrah et al., 2007). In addition, the ability 
of multifunctional Th1 cells to also secrete TNF 
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The quality of a Th1 response can be a prospective correlate of vaccine-mediated protec-
tion against certain intracellular pathogens. Using two distinct vaccine platforms, we 
evaluate the influence of interleukin (IL) 10 production on the magnitude, quality, and 
protective capacity of CD4+ T cell responses in the mouse model of Leishmania major 
infection. Multiparameter flow cytometry was used to delineate the CD4+ T cell production 
of interferon (IFN) , IL-2, tumor necrosis factor (TNF), and IL-10 (or combinations 
thereof) after vaccination. Immunization with a high dose of adenovirus (ADV) expressing 
leishmanial proteins (MML-ADV) elicited a limited proportion of multifunctional IFN-+ 
IL-2+TNF+ Th1 cells, a high frequency of IL-10–producing CD4+ T cells, and did not protect 
against subsequent challenge. Surprisingly, in the absence of IL-10, there was no change in 
the magnitude, quality, or protective capacity of the Th1 response elicited by high-dose 
MML-ADV. In contrast, after immunization with MML protein and CpG (MML + CpG),  
IL-10 limited the production of IL-12 by DCs in vivo, thereby decreasing the generation  
of multifunctional Th1 cells. Consequently, three immunizations with MML + CpG were  
required for full protection. However, inhibiting IL-10 at the time of immunization enhanced 
the magnitude and quality of the Th1 response sufficiently to mediate protection after only 
a single immunization. Overall, we delineate distinct mechanisms by which vaccines elicit 
protective Th1 responses and underscore the importance of multifunctional CD4+ T cells.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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could profoundly impact the efficiency and extent of Th1 
differentiation by regulating production of IL­12 by DCs. In 
this regard, we previously showed three immunizations with 
MML protein and the toll­like receptor (TLR) 9 ligand CpG 
(MML + CpG) are required to elicit a high frequency of 
multifunctional Th1 cells and protective immunity against 
L. major (Darrah et al., 2007). As CpG is a potent inducer of 
IL­10 and IL­12 from DCs (Chu et al., 1997; Roman et al., 
1997; Boonstra et al., 2006; Samarasinghe et al., 2006), we 
hypothesized that this innate cross­regulation after immu­
nization might influence the number of immunizations re­
quired to achieve protection and the type of Th1 response 
induced. Thus, the other major focus of the study was to 
examine the role IL­10 and IL­12 production from innate 
immune cells on Th1 immunity and protection after MML + 
CpG immunization.
In this study, we investigate how IL­10 production by 
CD4+ T cells or APCs might influence the magnitude, qual­
ity,  and  protective  capacity  of  Th1  responses  elicited  by 
MML­ADV or MML + CpG immunization. Thus, a novel 
multiparameter flow cytometry panel was developed to de­
fine the quality of the MML­specific response after vaccina­
tion, measured by the production of IL­10, IFN­, IL­2, and 
TNF. In addition, IL­10/ mice and WT mice treated with 
anti–IL­10 receptor (­IL­10R) were used to define the role 
of innate and adaptive IL­10 on vaccine­induced immunity 
and Th1­mediated protection. Overall, this study delineates 
the mechanisms of how two distinct vaccine formulations 
generate protective immunity and elucidates the role that IL­10 
has on this process.
RESULTS
Characterization of distinct cytokine-producing CD4+ T cell 
populations using multiparameter flow cytometry
Immunization with high­dose (1010 viral particles [vp]) and 
low­dose (107 vp) MML­ADV results in a similar magnitude 
of  IFN­–producing  CD4+  T  cells  but  only  low­dose 
MML­ADV confers durable protection (Darrah et al., 2007). 
One explanation for such findings is that low­dose MML­
ADV elicits a Th1 response of better quality than high­dose 
MML­ADV. However, it was recently shown that IL­10 
from CD4+ T cells contributes to susceptibility to L. major 
infection even in the presence of a strong Th1 response   
(Anderson et al., 2005, 2007). Thus, we developed a multipa­
rameter flow cytometry panel to investigate a role for CD4+ 
T cell–derived IL­10 in vaccine­mediated protection of 
mice after MML­ADV. Fig. 1 outlines the gating strategy, 
cytokine analysis, and data presentation used in this study. 
Shown is the gating of CD4+ T cells (Fig. 1 A) used to quan­
tify the total frequency of IFN­–, IL­2–, TNF­, or IL­10–
producing CD4+ T cells (Fig. 1 B), as well as the Boolean 
analysis (Fig. 1 C) and graphical representation (Fig. 1, D and E)   
of the 15 individual cytokine combinations of IFN­, IL­2, 
TNF, or IL­10 produced by individual CD4+ T cells. The 
proportion (of the total response) of each cytokine alone   
or  in  any  combination  produced  at  the  single­cell  level   
and IL­2 provides additional effector function and enhanced 
proliferative  capacity,  respectively,  making  these  cells  opti­
mized for durable effector function. The quality of a vaccine­
elicited response was first shown to be predictive of disease 
protection against Leishmania major in as much as a CD4+ T cell 
quality comprising a high frequency of multifunctional IFN­+ 
IL­2+TNF+ Th1 cells correlated with protection (Darrah et al., 
2007). Moreover, this Th1­based metric has since been cor­
related with a favorable outcome to a variety of other infec­
tions including tuberculosis (Forbes et al., 2008; Lindenstrøm 
et al., 2009), malaria (Roestenberg et al., 2009), and vaccinia 
(Trumpfheller et al., 2008).
As the quality of a Th1 response may predict outcome 
against infection, understanding the mechanisms that influence 
the generation of multifunctional Th1 cells can be used to im­
prove vaccine design. Using various vaccine formulations or 
by altering the dose of a specific vaccine, we were able to elicit 
qualitatively distinct Th1 responses that confer varying levels   
of protection. Indeed, vaccination with a single low dose of 
MML­adenovirus (ADV) elicited a Th1 response comprising a 
high frequency of multifunctional cells and protection against 
L. major challenge, whereas a single high dose of MML­ADV 
elicited fewer multifunctional cells, a high proportion of IFN­ 
single­positive cells, and no protection (Darrah et al., 2007). 
Although the lack of protection after high­dose MML­ADV 
immunization was consistent with a poor quality Th1 response, 
it remained possible that inhibitory cytokines, which have a 
well established role in limiting protection against L. major 
(Sacks and Anderson, 2004), were influencing outcome. In 
this regard, IL­10 produced by CD4+ T cells promotes suscep­
tibility and prevents healing in mice and humans infected with 
L. major (Sacks and Anderson, 2004). In the context of a self­
healing L. major infection, IL­10 from natural regulatory T (T reg) 
cells prevents the eradication of parasites, allowing a persistence 
of low­level antigen that sustains T cell memory (Belkaid et al., 
2001, 2002). Additionally, immune suppression during chronic 
L. major infection is mediated by IL­10 production from IFN­–
producing Th1 cells (Anderson et al., 2007). Thus, in the set­
ting of L. major infection in vivo, CD4+ T cell–derived IL­10 
prevents clearance of parasites. Alternatively, IL­10 produced 
by Th1 cells can have an important regulatory effect by limit­
ing excess inflammation during Toxoplasma gondii or Flu infec­
tion (Jankovic et al., 2002; Sun et al., 2009). Although these 
studies show that CD4+ T cell–derived IL­10 can have distinct 
regulatory effects on an ongoing infection in vivo, it has not 
been shown whether CD4+IFN­+IL­10+ Th1 cells can be 
elicited by vaccination with clinically based vectors or how 
they would influence the quality of the Th1 response or pro­
tection. Thus, a major focus of this study was to investigate a 
role for CD4+ T cell–derived (adaptive) IL­10 after immuniza­
tion with high­dose MML­ADV vaccination and to determine 
its effect on Th1 quality and protection.
IL­10 can also limit Th1 responses indirectly by decreas­
ing APC function or APC production of the canonical polar­
izing cytokine IL­12 (Moore et al., 2001; Trinchieri, 2001). 
Indeed, APC­derived (innate) IL­10 induced by vaccination JEM VOL. 207, July 5, 2010 
Article
1423
T  reg  cells  because  all  IL­10+  cells  were  confined  to  the 
CD4+CD25–Foxp3  population  (Fig.  S1).  In  assessing  the 
quality of the response 10 and 28 d after vaccination, high­dose 
MML­ADV elicited CD4+ T cells that produced antigen­ 
specific IL­10 alone or in combination with IFN­ or IFN­ 
and TNF (Fig. 2 B). It is of note that there were low to unde­
tectable populations of CD4+ T cells that produced both IL­10 
and  IL­2  (Fig.  2  B).  With  respect  to  IL­10  populations,   
high­dose MML­ADV elicited a lesser frequency of IFN­+ 
IL2+TNF+ multifunctional Th1 cells compared with low­dose 
MML­ADV (Fig. 2 B), which is consistent with our previous 
findings (Darrah et al., 2007). Thus, in comparing the overall 
quality  of  the  Th1  response,  high­dose  MML­ADV  elicits   
a heterogeneous CD4+ T cell cytokine response comprising a 
greater  proportion  of  IL­10–producing  cells  (Fig.  2  C, 
blue  arc)  and  a  lesser  proportion  of  IFN­+IL2+TNF+  
reflects the quality of the response and is illustrated using pie 
charts (Fig. 1 E).
High-dose MML-ADV immunization elicits a poor quality 
Th1 response and a high frequency of IL-10-producing 
CD4+ T cells
Consistent with our previous studies, the total frequency of 
IFN­–producing CD4+ splenocytes after i.m. vaccination of 
mice with high­dose MML­ADV (1010 vp) was greater than 
with low­dose MML­ADV (107 vp) at the peak of the im­
mune response (10 d after vaccination; Fig. 2 A, left) but equiv­
alent by the time of challenge (28 d after vaccination; Fig. 2 A 
[right]). Strikingly, a large frequency of IL­10–producing 
CD4+ T cells was detectable 10 and 28 d after vaccination with 
high­ but not low­dose MML­ADV (Fig. 2 A). The IL­10 
produced was antigen specific and not derived from natural   
Figure 1.  Characterization of 15 distinct 
cytokine-producing CD4+ T cell popula-
tions using multiparameter flow cytom-
etry. Typical gating tree and analysis for an 
eight-color flow cytometry panel used to 
simultaneously analyze IFN-–, IL-2–, TNF-, or 
IL-10–producing CD4+ T cells from a mouse 
spleen after in vitro stimulation with antigen, 
10 d after vaccination with high-dose MML-
ADV. (A) Initial gating of total events included 
a singlet cell gate, followed by selection for 
lymphocytes, live T cells (ViViDCD3+), and 
CD4+CD8 T cells. (B) The total frequency of 
antigen-specific IFN-–, IL-2–, TNF-, or IL-10–
producing CD4+ T cells is gated and graphed 
(background corrected) as shown. In this 
analysis, individual cells produce multiple 
cytokines; therefore, the frequency of cells 
producing any cytokine is less than the sum 
of the individual cytokine gates. (C) Boolean 
gating analysis of cytokine-positive popula-
tions separately categorizes each cell based 
on its functionality or quality with respect to 
cytokine production. Each responding cell is 
assigned to 1 of 15 possible combinations of 
IFN-, IL-2, TNF, or IL-10. (D and E) Boolean-
gated data in C are corrected for background 
and then presented either as a bar chart 
showing the frequency of each cytokine sub-
set (D) or as a pie chart illustrating the frac-
tion of the total response (E). In the pie chart 
shown, the numbers represent the order of 
cytokine subsets within the pie, the propor-
tion of multifunctional IFN-+IL-2+TNF+ Th1 
cells is depicted in red and the dark blue arc 
highlights the total proportion of IL-10–pro-
ducing cells. Note that for vaccinations that 
do not elicit IL-10, Boolean analysis of IFN-–, 
IL-2–, and TNF-producing cells yields seven 
distinct populations (not depicted).1424 Role of IL-10 in vaccine-elicited Th1 quality | Darrah et al.
IL-10 signaling does not influence the generation of Th1  
or IL-10–producing CD4+ T cells after immunization with 
high-dose MML-ADV
The next series of experiments focused on how IL­10 was 
elicited from CD4+ T cells after high­dose MML­ADV im­
munization and its effect, if any, on the quality of the immune 
response and protection. It is of note that IL­10 itself has been 
shown to give rise to antigen­specific IL­10 production from 
immunosuppressive CD4+ Tr1 cells (Groux et al., 1997). Thus, 
mice  were  treated  with  ­IL­10R  at  the  time  of  priming   
to determine whether inhibition of IL­10 signaling would   
influence the magnitude and quality of Th1 cells or IL­10– 
producing CD4+ T cells. Treatment with ­IL­10R at the 
time of i.m. (Fig. 3) or s.c. (Fig. S3) immunization with high­
dose MML­ADV did not significantly alter the total frequency 
(Fig. 3 A and Fig. S3 A) or the MFI (Fig. 3 B and Fig. S3 B) of 
IFN­–, IL­2–, TNF­, or IL­10–produc­
ing CD4+ T cells from the spleen 21 d 
later.  Thus,  IL­10  signaling  appeared  to 
have no role in priming for IL­10 produc­
tion by CD4+ T cells. Furthermore, the 
quality  of  the  response  after  high­dose 
MML­ADV was comparable in all mice 
independent of ­IL­10R treatment (Fig. 3, 
C and D; and Fig. S3, C and D). Accord­
ingly,  protection  after  high­dose  MML­
ADV vaccination was not enhanced in 
animals that received ­IL­10R treatment 
at the time of immunization, as determined 
by lesion progression (Fig. 3 E) or parasite 
burdens (not depicted).
multifunctional Th1 cells (Fig. 2 C, red pie slice) compared 
with low­dose MML­ADV. Additionally, in separate experi­
ments, similar results were observed using the s.c. route of im­
munization (Fig. S2).
The production of IL­10 by CD4+ T cells might counter­
act APC­activating signals to weaken pathogen­killing mecha­
nisms, accounting for the limited capacity of high­dose 
MML­ADV to protect. Alternatively, IL­10 might cause an 
intrinsic defect in Th1 function such as reduced potency of 
IFN­–producing effector populations that simultaneously se­
crete IL­10. In this regard, the IFN­ median fluorescent in­
tensity (MFI) of CD4+IFN­+IL­10+ T cells was not decreased 
compared with that of CD4+IFN­+IL­10 cells (Fig. 2 D), 
which is consistent with recently published data describing 
CD4+IFN­+IL­10+ T cell populations during infection with 
T. gondii (Jankovic et al., 2007).
Figure 2.  High-dose MML-ADV immuniza-
tion elicits IL-10–producing CD4+ T cells. 
MML-specific cytokine production by splenic 
CD4+ T cells 10 or 28 d after i.m. vaccination of 
mice with high- (1010 vp) or low- (107 vp) dose 
MML-ADV. (A–C) Multiparameter flow cytometry 
was used to quantify the total frequency of IFN-–,   
IL-2–, TNF-, or IL-10–producing CD4+ T cells (A), 
the frequency of cells expressing each of the 
fifteen possible combinations of IFN-, IL-2, TNF, 
or IL-10 (B) and the fraction of the total response 
represented by each of the fifteen individual cy-
tokine populations (C). For pie charts, multifunc-
tional Th1 cells are depicted in red and the blue 
arc highlights IL-10–producing cells. (D) The IFN- 
MFI of CD4+ T cells from mice vaccinated with 
high-dose MML-ADV (i.m. or s.c.) producing com-
binations of IFN-, TNF, or IL-10 10 d after vac-
cination. Bars show the median response from 
individual (n = 3–6) mice (dots; *, P < 0.05) for 
one of at least three experiments.JEM VOL. 207, July 5, 2010 
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with low­dose MML­ADV vaccination. Finally, in two sepa­
rate experiments the Th1 response elicited after i.m. or s.c.   
immunization with high­dose MML­ADV in the complete 
absence of IL­10 did not confer protection compared with 
low­dose MML­ADV, as determined by lesion progression 
(Fig. 4 D) or parasite burdens (Fig. 4 E). It is of note that lesion 
progression after challenge of IL­10/ mice was similar to 
what  we  have  previously  reported  in  WT  C57BL/6  mice 
(Darrah et al., 2007); however, IL­10/ mice displayed lower 
parasite burdens than WT mice irrespective of vaccination 
(unpublished data), which is consistent with previous results 
(Belkaid et al., 2001). Collectively, these data show no signifi­
cant effect of IL­10 by T cells or on T cells after high­dose 
MML­ADV immunization. Hence, the quality of the Th1 re­
sponse is a critical determinant of protection after high­dose 
MML­ADV vaccination, independent of IL­10 production.
MML + CpG, but not MML-ADV, immunization elicits IL-10 
and IL-12 production from innate immune cells
The prior data show that CD4+ T cell–derived IL­10 after 
high­dose MML­ADV immunization did not influence pro­
tection. Moreover, inhibiting IL­10 at the time of MML­ADV 
immunization had no effect on Th1 immunity. Although these 
data suggest that IL­10 is not involved in MML­ADV–induced 
Immunization with high-dose MML-ADV is not protective, 
even in the absence of IL-10
Because IL­10 from IFN­–producing CD4+ T cells has been 
shown to suppress parasite killing during chronic L. major in­
fection (Anderson et al., 2007), we next determined whether 
the limited protection after high­dose MML­ADV immuniza­
tion  was  a  result  of  vaccine­induced  IL­10  production  by 
CD4+ T cells, poor Th1 quality, or both. Thus, we vaccinated 
WT or IL­10/ mice with high­ or low­dose MML­ADV. 
In data from three combined experiments, the total frequency 
of IFN­–, IL­2–, or TNF­producing CD4+ T cells from the 
spleen 21 d after i.m. (Fig. 4 A) or s.c. (Fig. S4 A) immuniza­
tion  with  high­dose  MML­ADV  was  not  significantly  en­
hanced in IL­10/ mice compared with WT mice, which is 
consistent with the data in the previous section using ­IL­10R   
treatment. Moreover, the quality of the Th1 response gen­
erated in WT and IL­10/ mice was identical when com­
paring the same dose and route of MML­ADV vaccination 
(Fig. 4, B and C; and Fig. S4, B and C). Thus, in both WT and 
IL­10/ mice, high­dose MML­ADV vaccination elicits   
a qualitatively poor Th1 response, comprising a significantly 
smaller proportion of IFN­+IL2+TNF+ multifunctional Th1 
cells  and  a  significantly  larger  proportion  of  IFN­  single­ 
positive cells (Fig. 4, B and C; and Fig. S4, B and C) compared 
Figure 3.  IL-10 signaling does not affect 
the generation of Th1 or IL-10–producing 
CD4+ T cells after high-dose MML-ADV 
immunization. (A and B) MML-specific cyto-
kine production by splenic CD4+ T cells from WT  
mice treated with -IL-10R or Ctrl Ab at the 
time of immunization, 21 d after high- or low-
dose MML-ADV vaccination (i.m.). Shown are 
the total frequency (A) and MFI (B; note log 
scale) of IFN-–, IL-2–, TNF-, or IL-10–producing 
CD4+ T cells. (C and D) The percentage of the 
total CD4+ T cell response producing each of 
the 15 possible combinations of IFN-, IL-2, 
TNF, or IL-10 is illustrated in bar charts  
(C) showing the median response from indi-
vidual (n = 4) mice (dots; *, P < 0.05) and pie 
charts (D) showing the mean. For pie charts, 
multifunctional Th1 cells are depicted in red 
and the blue arc highlights the total proportion 
of IL-10–producing cells. Significant differ-
ences compared with low-dose MML-ADV are 
noted with p-values. NS, not significant. Data 
are representative of three experiments. (E) In a 
separate experiment, mice treated with -IL-10R 
(open circles) or Ctrl Ab (closed circles) at the 
time of immunization with high- or low-dose 
MML-ADV (i.m.) were challenged intradermally 
(i.d.) in the ear with live L. major 28 d after 
vaccination. Shown is the mean lesion size ± 
SEM over time after infection from at least  
12 ears per group. **, difference (6–10 wk;  
P < 0.05) from mice vaccinated by the same 
route with high-dose MML-ADV. Data are  
representative of two experiments.1426 Role of IL-10 in vaccine-elicited Th1 quality | Darrah et al.
immunity, we directly assessed production of IL­10 by innate 
immune  cells  in  vitro  and  in  vivo  after  stimulation  with 
MML­ADV. To extend the innate profile, IL­12 production 
was also examined. As shown in Fig. 5, there was no detect­
able IL­10 or IL­12 (p40 or p70) in the serum after vaccina­
tion with MML­ADV (Fig. 5 A) or from BMDC stimulated 
Figure 4.  The magnitude and quality of the Th1 response 
to high-dose MML-ADV immunization mice is not protec-
tive in IL-10/ mice. (A–C) MML-specific cytokine production 
by splenic CD4+ T cells from WT or IL-10/ mice 21 d after i.m 
vaccination with high- or low-dose MML-ADV. (A) The total fre-
quency of IFN-–, IL-2–, TNF-, or IL-10–producing CD4+ T cells.  
(B and C) The percentage of the total CD4+ T cell response pro-
ducing each of the seven possible combinations of IFN-, IL-2, or 
TNF is illustrated in bar charts (B) to show the median response 
from individual (n = 9–10) mice (dots; *, P < 0.05) and pie charts 
(C) to show the mean. IL-10 is excluded from the Boolean analy-
sis because the relevant comparison is to IL-10/ mice. For pie 
charts, multifunctional Th1 cells and IFN- single-positive cells 
are depicted in red and blue, respectively, and the black arc high-
lights the total proportion of IFN-–producing cells. Data are 
combined from three individual experiments. (D and E) 28 d after 
immunization, IL-10/ mice that had been vaccinated with 
high- or low-dose MML-ADV either i.m. or s.c. were challenged in 
the ear (i.d.) with live L. major. (D) Shown is the mean lesion size ± 
SEM over time from infected ears (n = 12 per group) for two 
separate experiments. **, area under the curve is different (P < 0.05) 
from mice vaccinated by the same route with high-dose MML-
ADV. (E) Shown is the number of parasites quantified from indi-
vidual draining LN at 5 wk after infection for one experiment. 
Error bars indicate the geometric mean of individual (n = 8) LN  
(*, P < 0.01). The gray line indicates the level of detection.
with MML­ADV in vitro (Fig. 5 B), although IL­12 
p40 was detected in LN DC immediately ex vivo after 
immunization compared with control mice (Fig. 5 C). 
However, there was no increase in IL­12 production 
in response to MML­ADV when IL­10 was absent or 
inhibited (Fig. 5, A­C). Thus, innate IL­10 produc­
tion has no influence on the magnitude, quality, or 
IL­10–producing capacity of Th1 cells after high­dose 
MML­ADV immunization.
The other vaccine formulation that we have previ­
ously studied for generating protective multifunctional 
Th1 responses against L. major in mice is MML protein 
with CpG (MML + CpG). With this vaccine approach, 
CpG promotes Th1 immunity through production of 
IL­12 from DCs (Chu et al., 1997; Roman et al., 1997; 
Fig.  5).  CpG  also  induces  production  of  IL­10 
from innate immune cells (Boonstra et al., 2006; 
Samarasinghe et al., 2006; Fig. 5, A and B). Impor­
tantly, inhibition of such innate IL­10, through use of 
either IL­10/ mice or ­IL­10R treatment, increases 
the amount of CpG­induced IL­12 p40 and IL­12 p70 
in the serum (Fig. 5 A) from BMDC stimulated in vitro 
(Fig. 5 B) and from LN DC ex vivo (Fig. 5 C).
The magnitude and quality of the Th1 response  
after MML + CpG immunization is enhanced  
in the absence of IL-10
Fig. 5 shows that IL­12 production by APCs can be signifi­
cantly increased by the inhibition of IL­10 during immuni­
zation with CpG; thus, we hypothesized that IL­10 may JEM VOL. 207, July 5, 2010 
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the efficiency of the MML + CpG vaccine regimen, mice 
were immunized once with MML + CpG in the presence 
(WT) or absence (IL­10/) of IL­10 or IL­10 signaling   
(­IL­10R treatment). As shown in Fig. 6 A, there was a   
dramatic increase in the total magnitude of IFN­–, IL­2–, 
and TNF­producing CD4+ T cells 23 d 
after a single vaccination with MML + CpG 
in the absence of IL­10 or IL­10 signaling 
compared with WT mice. It is of note 
that IL­10–producing CD4+ T cells were 
not detected after a single vaccination of 
limit Th1 differentiation when using a CpG vaccine regi­
men. In this regard, three immunizations with MML + CpG 
are required to elicit a high frequency of multifunctional 
Th1 cells and protection after vaccination (Darrah et al., 
2007). To assess whether manipulating IL­10 could enhance 
Figure 5.  CpG, but not MML-ADV, elicits innate IL-12 and IL-10. (A and B) Levels of IL-12 p40, IL-12 p70, or IL-10 protein in the serum (A) from 
WT and IL-10/ mice 2 and 6 h after injection (i.v.) of PBS, 50 µg CpG, or 1010 vp MML-ADV, or in the culture supernatant (B) from WT and IL-10/ 
BMDC after 6-, 12-, or 24-h stimulation with PBS, 1 µg/ml CpG, or 103 vp MML-ADV per BMDC measured by ELISA or cytometric bead array (CBA). Bars 
show the median response from individual mice (n = 4) or BMDC samples (n = 3). (C) Detection of IL-12 p40 (by intracellular staining [ICS]) from CD11c+ 
DCs or CD19+ B cells from pooled (n = 20) LN of Ctrl Ab– or -IL-10R–treated mice that were injected (s.c.) 6 h earlier with PBS, 50 µg CpG, or 1010 vp 
MML-ADV. Each dataset (A–C) is representative of two experiments (*, P < 0.05).
Figure 6.  Th1 responses to a single MML + CpG 
immunization are enhanced in the absence of  
IL-10. (A and B) MML-specific cytokine production 
by splenic CD4+ T cells from WT, IL-10/, or Ctrl Ab– 
or -IL-10R–treated WT mice 23 d after a single im-
munization of with MML + CpG. Shown is the total 
frequency (A) and MFI (B) of IFN-–, IL-2–, TNF-, or 
IL-10–producing CD4+ T cells. (C and D) Multifunc-
tional cytokine analysis. Shown is the absolute fre-
quency (C) and relative proportion (D) of each 
individual cytokine-producing population. For pie 
charts, multifunctional Th1 cells are depicted in red 
and a black arc highlights the total fraction of IFN-–
producing cells. Significant differences in quality are 
indicated by p-values. Bars show the median re-
sponse from individual (n = 4) mice (dots; *, P < 0.05). 
Data are representative of at least four experiments.1428 Role of IL-10 in vaccine-elicited Th1 quality | Darrah et al.
was blocked using ­IL­10R rather than using IL­10/ mice 
(Fig.  6,  A–D),  suggesting  that  compensatory  mechanisms 
might exist in IL­10/ mice.
The effect of IL-10 on enhancing the Th1 response  
to MML + CpG is IL-12 dependent
The dramatic change in magnitude and quality of the Th1 
response after a single vaccination of MML + CpG in the ab­
sence of IL­10 or IL­10 signaling (Fig. 6) was likely driven by 
an increase in IL­12 because CpG­induced IL­12 was signifi­
cantly enhanced in vitro and in vivo in the absence of IL­10 
(Fig. 5). Accordingly, when IL­10/ mice were treated with 
a neutralizing antibody to IL­12 (­IL­12) at the time of a 
single immunization with MML + CpG, the median fre­
quencies of IFN­, IL­2, and TNF compared with control 
antibody (Ctrl Ab)–treated IL­10/ mice were decreased by 
4.3­, 1.7­, and 1.9­fold, respectively (Fig. 7 A). Notably, 
the  frequency  of  IFN­+IL­2+TNF+  multifunctional  cells 
that produce high levels of IFN­ and correlate with protec­
tion  (Darrah  et  al.,  2007),  as  well  as  IFN­+IL­2TNF+  
T cells, was significantly decreased (4.1­ and 6.6­fold, respec­
tively) by ­IL­12 treatment (Fig. 7 B). Furthermore, the 
quality  of  the  Th1  response  in  ­IL­12–treated  MML  + 
CpG–immunized IL­10/ mice (Fig. 7 C) appeared less dif­
ferentiated than Ctrl Ab–treated IL­10/ mice, as the pro­
portion  of  cells  producing  only  TNF  or  TNF  and  IL­2 
(IFN­ negative) was greater (69 vs. 32%). This less differen­
tiated quality resembled the response in untreated WT mice 
receiving the same vaccine (Fig. 6 D, top). These data suggest 
that the neutralization of IL­12 effectively limited the extent 
of  vaccine­induced  Th1  differentiation  in  the  absence  of   
IL­10. Furthermore, immunization of IL­12 p40/ mice 
confirmed the role of IL­12 in driving the magnitude and 
differentiation of the Th1 response after MML + CpG vacci­
nation (Fig. S5). Lastly, ­IL­12 treatment of IL­10/ mice 
at the time of vaccination resulted not only in lower frequen­
cies of IFN­–producing Th1 populations but in IFN­+ 
IL­2+TNF+ and IFN­+IL­2TNF+ cells that secreted less 
IFN­ on a per cell basis (note log scale; Fig. 7 D) and less 
antigen­specific IFN­ production overall (Fig. 7 E) com­
pared with Ctrl Ab–treated vaccinated IL­10/ mice.
The effect of IL-10 on enhancing the Th1 response  
to MML + CpG is indirect
The previous data suggest that CpG­induced IL­10 limits the 
Th1 response to MML + CpG by restricting IL­12 production 
by APCs; however, a direct role for IL­10 on CD4+ T cells 
could not be excluded. To assess the in vivo mechanism for 
how vaccine­induced IL­10 influences Th1 immunity, BM 
chimera mice were generated by reconstituting irradiated   
Rag­1/ mice with equal numbers of CD45­disparate WT 
and IL­10R/ BM cells. Such mice provided a model to assess 
whether WT (IL­10R+/+) and IL­10R/ Th1 cells generated 
within the same animal and under identical innate conditions 
would differ in the magnitude or quality after MML + CpG 
vaccination. Rag­1/ control mice reconstituted with only 
MML + CpG. In addition, there was a significant increase in 
the IFN­, IL­2, and TNF MFI (note log scale; Fig. 6 B), sug­
gesting an underlying difference in the quality of the response. 
Indeed, of the four cytokine­producing populations that were 
significantly increased in the absence of IL­10 or IL­10 signal­
ing, the most striking increase was in the multifunctional   
(IFN­+IL­2+TNF+) CD4+ T cells (Fig. 6 C) that produce 
significantly more IFN­ (and therefore have a higher IFN­ 
MFI) than double or single IFN­–producing CD4+ T cells 
and correlate with protection against L. major (Darrah et al., 
2007). Thus, whereas WT animals generated low frequencies 
of predominantly TNF­ or TNF­ and IL­2–producing cells, 
animals vaccinated once with MML + CpG in the absence or 
blocking of IL­10 had a higher response with increased differ­
entiation toward IFN­–producing cells (Fig. 6 D). It is of 
note that we consistently noted a greater effect when IL­10 
Figure 7.  Enhanced Th1 responses to MML + CpG immunization in 
IL-10/ mice are IL-12–dependent. IL-10/ mice were treated with 
-IL-12 or Ctrl Ab at the time of a single immunization of MML + CpG. 
MML-specific cytokine responses in the spleen were determined 21 d 
later. (A) The total frequency of IFN-–, IL-2–, or TNF-producing CD4+  
T cells. (B–D) Multifunctional cytokine analysis. Shown is the absolute 
frequency (B) and relative proportion (C) of each cytokine-producing pop-
ulation. For pie charts, multifunctional Th1 cells are depicted in red and a 
black arc highlights the total fraction of IFN-–producing cells. Signifi-
cant differences are indicated by p-values. (D) The MFI of IFN-–producing 
CD4+ T cell populations. (E) IFN- secretion from total splenocytes 
measured by ELISA. Bars show the median responses from individual (n = 4) 
mice (dots; *, P < 0.05). Data are representative of two experiments.JEM VOL. 207, July 5, 2010 
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In this paper, we have demonstrated that ­IL­10R 
treatment at the time of immunization dramatically 
enhances the magnitude and quality of the Th1 re­
sponse to a single vaccination with MML + CpG. 
Thus,  we  sought  to  determine  how  Th1  re­
sponses  elicited  by  a  single  immunization  of 
MML + CpG in the presence of ­IL­10R compared with   
those elicited by three consecutive vaccinations in WT mice. 
When Th1 responses were analyzed 21 d after one (1×), two 
(2×), or three (3×) MML + CpG vaccinations with Ctrl Ab 
in WT mice, there was a clear hierarchy in the frequency 
(Fig. 9 A) and proportion (Fig. 9 B) of IFN­+IL­2+TNF+ 
and  IFN­+IL2TNF+  Th1  cells  that  correlated  with  the 
number of vaccinations. These data indicate that repetitive 
vaccination drives Th1 differentiation and are consistent with 
a linear differentiation model (Seder et al., 2008). Notably, the 
response elicited by a single vaccination of MML + CpG in 
WT mice treated with ­IL­10R (1× + ­IL­10R) appeared 
remarkably similar to the response observed in mice vacci­
nated 3× + Ctrl Ab, with respect to the frequency of multi­
functional cells (Fig. 9 A) as well as the overall proportion of 
IFN­–producing cells (Fig. 9 B, black arc). To further as­
sess whether these populations of CD4+ T cells were func­
tionally equivalent, we compared their proliferative capacity, 
avidity for peptide, and ability to confer protection. Com­
pared with 3×­vaccinated mice, CD4+ T cells from 1× + 
­IL­10R–vaccinated mice proliferated to the same ex­
tent (Fig. S6 A) and, in preliminary studies, had comparable 
functional avidity (EC50: 1× + ­IL­10R, 70 ng/ml; 3×,   
80 ng/ml; Fig. S6 B). The only evidence for a functional differ­
ence between mice receiving these vaccine regimens was in the 
trafficking of antigen­specific cells into the site of infection   
after L. major challenge. At 10 d after challenge, a significantly 
WT cells had low but detectable frequencies of IFN­–, IL­2–, 
or TNF­producing CD4+ T cells after only a single vaccina­
tion of MML + CpG (Fig. 8 A). In contrast, much higher Th1 
responses were measured in Rag­1/ control mice reconsti­
tuted with only IL­10R/ BM, in which all cells (including 
T cells and APCs) are refractory to IL­10 (Fig. 8 B). In mixed 
chimeric mice immunized with MML + CpG (Fig. 8, C–E), 
paired comparisons of WT and IL­10R/ cytokine frequen­
cies within the same mouse failed to demonstrate significant 
differences (Fig. 8 C) in two separate experiments (note sym­
bols). Despite variation in the magnitude of cytokine produc­
tion between mice, the ratio of IL­10R/ to WT cytokine 
frequencies within the same mouse (Fig. 8 D) was consistent 
and was not significantly different than 1.0 (equal response   
ratio). Furthermore, there were no significant differences (by 
paired analysis) in the frequency of multifunctional cells be­
tween WT and IL­10R/ Th1 cells (Fig. 8 E) or in the ca­
pacity of these populations to produce IFN­ (Fig. 8 F). These 
data show that the restrictive effect of IL­10 on Th1 generation 
and differentiation after MML + CpG vaccination is not di­
rectly on T cells but on APCs to limit IL­12 production.
A single immunization with MML + CpG in the absence  
of IL-10 confers protection
We previously reported that three immunizations with MML +   
CpG elicits a high frequency of multifunctional IFN­+IL­2+ 
TNF+ Th1 cells and confers protection (Darrah et al., 2007). 
Figure 8.  The influence of IL-10 on Th1 responses 
elicited by MML + CpG immunization is indirect. MML-
specific cytokine production by splenic CD4+ T cells from 
BM-reconstituted irradiated Rag-1/ mice 21 d after a sin-
gle immunization with MML + CpG. (A–C) The frequency of 
WT or IL-10R/ CD4+ T cells in blood at time of vaccination 
(left) and the total frequency of IFN-–, IL-2–, TNF-, or IL-10– 
producing WT or IL-10R/ CD4+ splenocytes (right) from 
vaccinated Rag-1/ mice that had been reconstituted 5 mo 
earlier with WT BM only (A; n = 4), IL-10R/ BM only  
(B; n = 2), or mixed BM (C; n = 8). (D) The cytokine response 
ratio for IFN-, IL-2, and TNF, calculated as the IL-10R/ 
response (percentage of IL-10R/ CD4+ T cells) divided by 
the WT response (percentage of WT CD4+ T cells) within the 
same chimeric mouse. The median ratio from individual chimeric 
mice (n = 8) is indicated by horizontal bars. (E and F)  
Multifunctional analysis of WT or IL-10R/ CD4+ T cell  
responses from mixed BM chimera mice after vaccination. 
Shown are the absolute frequency (E) of each cytokine- 
producing population and the MFI (F) of IFN-–producing 
populations. Bars show the median response from individual 
mice (dots) combined from two separate experiments  
(indicated by open or closed symbols).1430 Role of IL-10 in vaccine-elicited Th1 quality | Darrah et al.
determined by ear lesion progression over time (Fig. 9 C) or 
parasite burdens (Fig. 9 D). Thus, blocking the effects of IL­10 
only at the time of immunization converted the low magni­
tude and less differentiated quality elicited by a single MML + 
CpG vaccination into a robust vaccine that elicits a high fre­
quency of multifunctional Th1 cells and protects as well as 
three vaccinations in WT mice.
DISCUSSION
In this paper, we extend our previous findings that a Th1 re­
sponse of a particular quality is necessary to mediate protection 
against an intracellular infection, using two different vaccine 
modalities. Our study focused on the influence of vaccine­ 
induced IL­10 from CD4+ T cells or APCs on the magnitude, 
quality, and protective capacity of the Th1 response. The data 
show a dose­dependent increase in IL­10 production by CD4+ 
T cells after immunization with MML­ADV; however, such 
CD4+ T cell­derived adaptive IL­10 did not impact Th1 im­
munity or protection. In contrast, inhibition of innate IL­10 
produced by APCs at the time of immunization with MML + 
CpG significantly enhanced the magnitude of the response and 
the extent of Th1 differentiation and, importantly, increased 
protection. Together, these data demonstrate how IL­10 can 
be manipulated to achieve favorable Th1 quality and protec­
tion, depending on the vaccine platform. The mechanisms un­
derlying these findings should inform vaccine design against 
infections requiring Th1 responses for protection.
In choosing specific vaccine platforms, recombinant ADV 
vectors are of broad interest based on their potential use as   
vaccines to prevent HIV, malaria, and tuberculosis infection. 
Among the various ADV serotypes, serotype 5 is the most po­
tent inducer of T cell responses (Thorner et al., 2006). In this 
paper, we show that low­dose MML­ADV elicits a favorable 
Th1 quality and very few IL­10–producing CD4+ T cells, and 
it protects mice from L. major challenge. In contrast, high­dose 
MML­ADV elicits a poor quality Th1 response and a high   
frequency of IL­10–producing CD4+ T cells, and it does not 
protect. Further characterization of the Th1 response to high­
dose MML­ADV at the single­cell level revealed that a major­
ity  of  the  IL­10  produced  was  from  CD4+CD25Foxp3  
T cells that also produced IFN­ with or without TNF, which 
is indicative of a Th1 lineage. Several recent studies have dem­
onstrated dramatic effects of CD4+ T cell–derived IL­10   
in vivo in the context of ongoing infection. In this regard, IL­10 
production by CD4+IFN­+ Th1 cells limits an excessive pro­
inflammatory response during the course of T. gondii (Jankovic 
et al., 2007) and Flu infections (Sun et al., 2009). Furthermore, 
in the setting of chronic L. major infection, production of IL­10 
by CD4+IFN­+ Th1 cells limits parasite killing and protec­
tion (Anderson et al., 2007). With regard to vaccines, ­IL­10R   
treatment increased vaccine­elicited protection in the BALB/c 
model of L. major infection (Stober et al., 2005). In the latter 
study,  it  was  speculated  that  blocking  IL­10  derived  from 
CD4+CD25+ Tr1­like cells during the course of infection en­
hanced protection (Stober et al., 2005). Given the findings in 
the L. major model, we hypothesized that IL­10–producing 
larger frequency of Th1 cells had migrated into the ears of 
mice vaccinated 3× with MML + CpG compared with mice 
vaccinated 1× + ­IL­10R (Fig. S7). However, despite the 
difference in frequency of antigen­specific Th1 cells in the 
ear shortly after infection, mice vaccinated 1× + ­IL10R 
were protected as well as those vaccinated 3× + Ctrl Ab as   
Figure 9.  A single immunization with MML + CpG in the absence of 
IL-10 signaling elicits protection. Comparison of the immune response 
and subsequent protection in mice that received one (1×), two (2×), or three 
(3×) immunizations of MML + CpG (+ Ctrl Ab) to -IL-10R–treated mice 
that received a single immunization of MML + CpG (1× + -IL-10R). (A and 
B) Multifunctional analysis of the MML-specific CD4+ T cell response from 
the spleen 21 d after immunization. Shown is the absolute frequency (A) 
and the relative proportion (B) of each individual combination of IFN-–,  
IL-2–, or TNF-producing cells. Bars show the median response from indi-
vidual (n = 4–5) mice (dots; *, P < 0.05). For pie charts, multifunctional Th1 
cells are depicted in red and a black arc highlights the total fraction of  
IFN-–producing cells. Data are representative of three experiments.  
(C and D) Vaccine-elicited protection in mice challenged with live L. major 
35 d after immunization. (C) Mean lesion size ± SEM over time from infected 
ears (n = 12 per group). **, different (5–8 wk; P < 0.05) from unvaccinated 
and 1×-vaccinated (+ Ctrl Ab) mice. (D) Parasite burdens were determined  
7 wk after infection using real-time PCR. Horizontal bars show the  
geometric means of individual (n = 12) ears (*, P < 0.05). Data comparing 
1× MML + CpG vaccination with and without -IL-10R treatment are  
representative of three experiments.JEM VOL. 207, July 5, 2010 
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The data from the MML + CpG vaccinations provide a 
mechanism for why multiple immunizations are required to 
elicit a frequency of multifunctional Th1 cells sufficient for 
protection using a protein vaccine with a TLR ligand that in­
duces both IL­10 and IL­12. IL­10 can protect the host   
by down­regulating IL­12–driven proinflammatory Th1 re­
sponses during infection with T. gondii or influenza or expo­
sure to LPS (Gérard et al., 1993; Howard et al., 1993; Jankovic 
et al., 2007; Sun et al., 2009). However, the same negative 
feedback limits Th1 generation and differentiation when adapt­
ing the constituents of such pathogens as vaccine adjuvants. 
The finding that limiting IL­10 can dramatically enhance Th1 
responses generated by protein and TLR ligand­based vaccine 
formulations has implications for improving vaccine design in 
humans. Most protein­based vaccines must be given several 
times over a prolonged period of time to induce a protective 
response. If transient inhibition of IL­10 improves the effi­
ciency of vaccination so that fewer immunizations are required, 
it might increase compliance and save cost in resource­poor 
areas. In this regard, inclusion of p38 MAPK inhibitor in­
creased the protection of a low­dose CpG­based pertussis vac­
cine regimen through inhibition of T reg cell–derived IL­10, 
although a specific effect on the Th1 response was not demon­
strated (Jarnicki et al., 2008).
This paper shows the effects of IL­10 by CD4+ T cells and 
APCs in the context of protection using different vaccine regi­
mens. Indeed, we demonstrate that three vaccines (low­dose 
MML­ADV, 3× MML + CpG, and 1× MML + CpG + ­
IL­10R)  elicited  Th1  responses  of  comparable  frequency, 
quality, and level of protection. Importantly, the mechanisms 
by which these vaccines elicit such responses appear distinct 
vis­à­vis the role of innate immunity, antigen dose, persistence, 
and  repetitive  immunization.  We  have  incorporated  these 
variables in our model of Th1 differentiation (Fig. S8). In con­
clusion, balancing the extent of Th1 differentiation to achieve 
protective and durable Th1 immunity remains a hurdle for   
developing vaccines for infections such as leishmaniasis and   
tuberculosis. This study provides insight into how vaccines   
can be manipulated to achieve protective immunity.
MATERIALS AND METHODS
Mice.  Female  C57BL/6  (B6),  B6.IL­10/,  B6.IL­10R/,  B6.IL­12 
p40/, B6.CD45.1, and B6.RAG­1/ were obtained from The Jackson 
Laboratory. BM chimeras were generated by injecting 2.5 × 106 BM cells 
from B6.IL­10R/ (CD45.2) and WT B6.CD45.1 mice into irradiated 
(650 rad) B6.Rag­1/ mice. All mice were maintained in animal care facili­
ties at the National Institutes of Health under pathogen­free conditions and 
all experiments were approved by the Vaccine Research Center animal care 
and use committee.
Immunizations and in vivo mAb treatment. MML (also known as 
Leish­111f) is a recombinant polyprotein derived from Leishmania species, 
shown  to  be  protective  in  vivo,  and  comprising  three  proteins:  TSA   
(also known as MAPS), LmSTI1 (also known as M15), and LeIF (Skeiky   
et al., 2002). Mice were immunized once with 1010 or 107 vp (16 vp per 
infectious unit) of replication­defective ADV serotype 5 expressing MML 
(MML­ADV; provided by S.G. Reed, Infectious Disease Research Institute, 
Seattle, WA) either i.m. (leg) or s.c. (foot). 25 µg MML protein (SAIC­Frederick, 
CD4+ T cells elicited by high­dose MML­ADV immunization 
limited control of infection. Surprisingly, in the absence of   
IL­10 or IL­10 signaling at the time of vaccination or through­
out the infection, the magnitude or the quality of the Th1 
response after high­dose MML­ADV immunization was not 
enhanced nor was the protection improved. As we were unable 
to demonstrate production of other inhibitory cytokines (IL­4, 
IL­13, and TGF­) from CD4+ T cells after high­dose 
MML­ADV immunization (unpublished data), these data un­
derscore that the quality of the Th1 response is a necessary de­
terminant of protection against L. major infection. Because a 
single immunization with MML­ADV can confer protection 
when given at a lower dose, it is likely that the quality of the re­
sponse can be negatively impacted by the vector providing 
more antigen, altered innate immunity, or both. Studies to ana­
lyze the effect of each of these variables on the quality of the 
Th1 response are underway.
The other vaccine formulation analyzed in this study was 
MML + CpG. Protein vaccines formulated with TLR ligands, 
such as monophosphoryl lipid A, are currently being tested in 
humans for prevention of leishmaniasis, tuberculosis, and ma­
laria (Coler and Reed, 2005; Skeiky and Sadoff, 2006; Coler   
et al., 2009). They offer an advantage over certain viral vaccines 
in that they potently elicit both antibody and Th1 responses 
and can be used repetitively. Paradoxically, some TLR ligands, 
such as CpG or LPS, can prime Th1 responses through induc­
tion of IL­12 but also elicit the inhibitory cytokine IL­10   
(Chu et al., 1997; Roman et al., 1997; Boonstra et al., 2006; 
Samarasinghe et al., 2006). Thus, we hypothesized that Th1 
responses would be significantly altered by inhibiting IL­10   
after vaccination with MML + CpG. Indeed, ­IL­10R treat­
ment has been shown to enhance the Th1 recall response to 
soluble ovalbumin protein when primed in the presence of the 
LPS (Castro et al., 2000). In this paper, we extended these 
findings by defining the role that IL­10 has in the magnitude 
and quality of the Th1 response at the single­cell level in a 
model that allowed us to assess vaccine­elicited protection. 
CpG elicited high amounts of innate IL­12 (p40 and p70) and 
IL­10 in the serum after injection or from BMDCs stimulated 
in vitro; moreover, IL­12 levels were enhanced in IL­10/ 
mice. In addition, the amount of IL­12 expressed ex vivo by 
LN DCs isolated after CpG immunization was higher when 
IL­10 signaling was inhibited. Such perturbations in IL­10 
production also had a striking effect on vaccine­elicited Th1 
responses. Vaccination of IL­10/ or ­IL­10R–treated mice 
with a single injection of MML + CpG dramatically increased 
the magnitude of the Th1 response, altered the Th1 quality, 
and enhanced protection compared with a single vaccination 
of WT mice in an IL­12–dependent manner. Last, MML + 
CpG vaccination of BM chimera mice revealed no difference 
in a WT or IL­10R/ Th1 response generated under identi­
cal innate conditions within the same mouse, ruling out a di­
rect role of IL­10 on CD4+ T cells. Thus, innate IL­10 inhibits 
IL­12 production from DCs and limits the extent of Th1 dif­
ferentiation in response to a transient amount of protein antigen 
when given with CpG.1432 Role of IL-10 in vaccine-elicited Th1 quality | Darrah et al.
Proliferation assay. Splenocytes harvested from mice 17 d after vaccination 
were labeled with 0.25 µM CFSE (Invitrogen) at a concentration of 1.0 ×   
106 cells/ml in PBS for 7 min at 37°C. Cells were washed and cultured in dupli­
cate at a concentration of 3.0 × 106 cells/ml/tube in the presence of 5 µg/ml 
MML for 5–6 d, protected from light. For the final 7 h, 1 µg/ml (each) MML 
peptides and 10 µg/ml BFA were added, followed by ICS as described in Multi­
parameter flow cytometry. A mean of 105 live T cells were analyzed per sample.
Statistics. All cytokine frequencies are reported after background subtraction 
of the frequency of the identically gated population of cells from the same 
sample stimulated without antigen. Bars in figures show the median of indi­
vidual mice (dots in figures). Total spleen cell counts and total numbers of   
viable CD4+ T cells were not significantly different between vaccine groups 
within the same experiment. All comparisons (bar and pie charts) of cytokine 
production between vaccine groups were done in SPICE v4.2.3 using a two­
tailed Student’s t test assuming unequal variances or Wilcoxin­rank test (for   
n ≥ 4 mice). For BM chimeras, a paired analysis (t test and Wilcoxin) was used 
to compare responses of BM subsets within the same mouse. For challenge 
data, area under the curve or lesion sizes at individual time points were com­
pared by Student’s t test using SigmaPlot (version 8; Systat Software Inc.) or 
JMP v5.1 (SAS Institute Inc.). Avidity was determined by a nonlinear least­
squares fit of a standard Michaelis­Menten binding curve using JMP (version 
5.1). Significance was determined by comparing the EC50 (effective concen­
tration that elicits half of the maximum response) for titrations from each in­
dividual mouse. For all comparisons, p­values <0.05 are noted.
Online supplemental material. Fig. S1 shows that high­dose MML­ADV 
does not induce T reg cells and elicits IL­10 from CD4+CD25Foxp3  
T cells. Fig. S2 shows that s.c. immunization with high­dose MML­ADV 
vaccination elicits IL­10–producing CD4+ T cells. Fig. S3 shows that block­
ing IL­10 signaling at the time of s.c. immunization with high­dose MML­
ADV does not influence the generation of Th1 or IL­10–producing CD4+ 
T cells. Fig. S4 demonstrates that IL­10 does not impact the magnitude, 
quality, or protective capacity of the Th1 response after s.c. immunization 
with high­dose MML­ADV. Fig. S5 confirms the role of IL­12 p40 in driv­
ing the magnitude and differentiation of the Th1 response after MML + 
CpG vaccination. Fig. S6 demonstrates that antigen­specific CD4+ T cells 
generated after vaccination with 3× MML + CpG or 1× MML + CpG + 
­IL­10R display comparable proliferation and functional avidity in vitro. 
Fig. S7 shows antigen­specific CD4+ T cells in the ear after L. major chal­
lenge of mice vaccinated with MML + CpG. Fig. S8 illustrates a model for 
linear differentiation of Th1 and IL­10–producing CD4+ T cells.
MML-ADV and MML DNA was provided by S.G. Reed (Infectious Disease Research 
Institute, Seattle, WA). Antibodies to IL-10R and IL-12 were provided by F.D. 
Finkelman (University of Cincinnati). Assistance in generation of BM chimera mice 
was provided by K.E. Foulds (National Institutes of Health [NIH]).
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